Article Abstract

Pacific Rim redux: lorlatinib, the ultimate Jaeger?

Authors: Viola W. Zhu, Sai-Hong Ignatius Ou


Lorlatinib is the most potent anaplastic lymphoma kinase (ALK) inhibitor to date based on pre-clinical models and also has excellent central nervous system penetration with an efflux/influx ratio of 1.5 (1). Emerging phase 1/2 data have demonstrated its efficacy in patients after disease progression on first- and second-generation ALK inhibitors (2).